Current Strategies for Treating NSCLC: From Biological Mechanisms to Clinical Treatment

The identification of specific epidermal growth factor receptor (EGFR)-activating mutations heralded a breakthrough in non-small-cell lung cancer (NSCLC) treatments, with the subsequent development of EGFR-tyrosine kinase inhibitor (TKIs) becoming the first-line therapy for patients harboring EGFR m...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Junnan, Kwok, Hang Fai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7352656/
https://www.ncbi.nlm.nih.gov/pubmed/32549388
http://dx.doi.org/10.3390/cancers12061587

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7352656/
https://www.ncbi.nlm.nih.gov/pubmed/32549388
http://dx.doi.org/10.3390/cancers12061587

Ejemplares similares